View Financial HealthBeximco Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 5/6Beximco Pharmaceuticals 수익으로 충분히 충당되는 현재 수익률 3.09% 보유한 배당금 지급 회사입니다.핵심 정보3.1%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률9.1%배당 성장률17.6%다음 배당 지급일n/a배당락일30 Jul 26주당 배당금n/a배당 성향24%최근 배당 및 자사주 매입 업데이트공시 • Jun 24Beximco Pharmaceuticals PLC Proposes Cash Dividend for the Year Ended 30 June, 2025Beximco Pharmaceuticals PLC. proposed 47.5% Cash Dividend (BDT 4.75 per Share) for the year ended 30 June, 2025. Record date is 2 August 2026.공시 • Dec 30Beximco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended on 30 June 2024, Payable on or Before 28 January 2025Beximco Pharmaceuticals Limited announced that at the AGM held on 29 December 2024, the resolutions passed at the AGM included the approval of 40% cash dividend for the year ended on 30 June 2024. The cash dividend being 40% of the nominal value per ordinary share of BDT 10 (BDT 4.0 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR holders' as on the date of record, i.e. 25 November 2024) on or before 28 January 2025. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.공시 • Jan 19Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022Beximco Pharmaceuticals Limited announced that the 35% cash dividend of the nominal value per ordinary share/GDR (Taka 3.50 per ordinary share/GDR) for the year ended 30 June 2022, which was approved in the Annual General Meeting ("AGM") held on 22 December 2022, has been deposited with the custodian bank in Dhaka on 18 January 2023 for onward credit to respective GDR holders' accounts.모든 업데이트 보기Recent updates공시 • Jun 24Beximco Pharmaceuticals PLC Proposes Cash Dividend for the Year Ended 30 June, 2025Beximco Pharmaceuticals PLC. proposed 47.5% Cash Dividend (BDT 4.75 per Share) for the year ended 30 June, 2025. Record date is 2 August 2026.공시 • Jun 22+ 2 more updatesBeximco Pharmaceuticals PLC. to Report Fiscal Year 2025 Results on Jun 23, 2026Beximco Pharmaceuticals PLC. announced that they will report fiscal year 2025 results on Jun 23, 2026공시 • Mar 06Beximco Pharmaceuticals PLC Provides Update on Writ PetitionsBeximco Pharmaceuticals PLC had provided an update regarding the timeline for its outstanding Writ Petitions to be heard by the High Court Division of the Supreme Court of Bangladesh. Further to previous announcements, the hearing of Writ Petition No. 525 of 2025 (challenging the proposed appointment by the Bangladesh Securities and Exchange Commission of nine additional independent non-executive directors to the Company's Board) and Writ Petition No. 1243 of 2026 (challenging the BSEC's order to hold a Board Meeting onboarding the nine additional independent directors) will now commence after the scheduled vacation (from March 15, 2026 to April 18, 2026) of the High Court Division of the Supreme Court of Bangladesh.공시 • Jan 29Beximco Pharmaceuticals Limited Announces Board ChangesBeximco Pharmaceuticals Limited announced that Ms. Quamrun Naher Ahmed, a Non-Executive Director since 30 November 2020, has been replaced by Mr. Mohammed Ebtadul Islam, both with immediate effect. Mr. Islam, like Ms. Ahmed previously, has been nominated to this position by IFIC Bank PLC, a shareholder in the Company, and he will serve as a Non-Executive Director. Mr. Islam has extensive expertise in finance and management at a senior level, having worked at Bangladesh Bank, the central bank of Bangladesh, for 33 years, retiring as an Executive Director in 2014. He currently serves as an independent director of IFIC Bank PLC. He is also a Supernumerary Professor at the Bangladesh Institute of Bank Management (BIBM), the national educational institute on banking and finance in Bangladesh.공시 • Jan 23Beximco Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 28, 2025Beximco Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 28, 2025공시 • Dec 30Beximco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended on 30 June 2024, Payable on or Before 28 January 2025Beximco Pharmaceuticals Limited announced that at the AGM held on 29 December 2024, the resolutions passed at the AGM included the approval of 40% cash dividend for the year ended on 30 June 2024. The cash dividend being 40% of the nominal value per ordinary share of BDT 10 (BDT 4.0 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR holders' as on the date of record, i.e. 25 November 2024) on or before 28 January 2025. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.공시 • Nov 08Beximco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024Beximco Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 13, 2024공시 • Oct 30Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024, at 10:30 Central Asia Standard Time.공시 • Oct 23Beximco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024Beximco Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 28, 2024공시 • Apr 24Beximco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024Beximco Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 29, 2024공시 • Jan 22Beximco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024Beximco Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 29, 2024공시 • Jan 12Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing DirectorBeximco Pharmaceuticals Limited announced stepping down of Mr. Nazmul Hassan MP as Managing Director with immediate effect. This follows an invitation from the Prime Minister for Mr. Hassan to join the newly formed Cabinet as a Minister after the recent Bangladesh Parliamentary Election on 7 January 2024.공시 • Jan 11Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the BoardBeximco Pharmaceuticals Limited announced stepping down of Mr. Nazmul Hassan as Member of the Board with immediate effect. The process to find a replacement will commence immediately and the Company will provide an update at the appropriate time.공시 • Oct 30Beximco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 05, 2023Beximco Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 05, 2023공시 • Oct 20+ 2 more updatesBeximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023, at 10:30 Coordinated Universal Time.공시 • Jan 19Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022Beximco Pharmaceuticals Limited announced that the 35% cash dividend of the nominal value per ordinary share/GDR (Taka 3.50 per ordinary share/GDR) for the year ended 30 June 2022, which was approved in the Annual General Meeting ("AGM") held on 22 December 2022, has been deposited with the custodian bank in Dhaka on 18 January 2023 for onward credit to respective GDR holders' accounts.예정된 배당 지급오늘Jul 11 2026배당락일Jul 30 20260다음 배당금을 받으려면 앞으로 19 days일 이내에 매수하세요0지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: BXP 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.배당금 증가: BXP 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Beximco Pharmaceuticals 배당 수익률 vs 시장BXP의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BXP)3.1%시장 하위 25% (GB)2.1%시장 상위 25% (GB)5.5%업계 평균 (Pharmaceuticals)2.6%분석가 예측 (BXP) (최대 3년)9.1%주목할만한 배당금: BXP 의 배당금( 3.09% )은 UK 시장에서 배당금 지급자의 하위 25%( 2.07% )보다 높습니다.고배당: BXP 의 배당금( 3.09% )은 UK 시장에서 배당금 지급자의 상위 25%( 5.52% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 지급 비율 ( 24.5% )이 낮기 때문에 BXP 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 30.7% )로 BXP 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YGB 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/10 07:06종가2026/07/10 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Beximco Pharmaceuticals PLC.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Asif KhanEDGE Research & ConsultingLorenza CastellonEquity Development Limited
공시 • Jun 24Beximco Pharmaceuticals PLC Proposes Cash Dividend for the Year Ended 30 June, 2025Beximco Pharmaceuticals PLC. proposed 47.5% Cash Dividend (BDT 4.75 per Share) for the year ended 30 June, 2025. Record date is 2 August 2026.
공시 • Dec 30Beximco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended on 30 June 2024, Payable on or Before 28 January 2025Beximco Pharmaceuticals Limited announced that at the AGM held on 29 December 2024, the resolutions passed at the AGM included the approval of 40% cash dividend for the year ended on 30 June 2024. The cash dividend being 40% of the nominal value per ordinary share of BDT 10 (BDT 4.0 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR holders' as on the date of record, i.e. 25 November 2024) on or before 28 January 2025. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.
공시 • Jan 19Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022Beximco Pharmaceuticals Limited announced that the 35% cash dividend of the nominal value per ordinary share/GDR (Taka 3.50 per ordinary share/GDR) for the year ended 30 June 2022, which was approved in the Annual General Meeting ("AGM") held on 22 December 2022, has been deposited with the custodian bank in Dhaka on 18 January 2023 for onward credit to respective GDR holders' accounts.
공시 • Jun 24Beximco Pharmaceuticals PLC Proposes Cash Dividend for the Year Ended 30 June, 2025Beximco Pharmaceuticals PLC. proposed 47.5% Cash Dividend (BDT 4.75 per Share) for the year ended 30 June, 2025. Record date is 2 August 2026.
공시 • Jun 22+ 2 more updatesBeximco Pharmaceuticals PLC. to Report Fiscal Year 2025 Results on Jun 23, 2026Beximco Pharmaceuticals PLC. announced that they will report fiscal year 2025 results on Jun 23, 2026
공시 • Mar 06Beximco Pharmaceuticals PLC Provides Update on Writ PetitionsBeximco Pharmaceuticals PLC had provided an update regarding the timeline for its outstanding Writ Petitions to be heard by the High Court Division of the Supreme Court of Bangladesh. Further to previous announcements, the hearing of Writ Petition No. 525 of 2025 (challenging the proposed appointment by the Bangladesh Securities and Exchange Commission of nine additional independent non-executive directors to the Company's Board) and Writ Petition No. 1243 of 2026 (challenging the BSEC's order to hold a Board Meeting onboarding the nine additional independent directors) will now commence after the scheduled vacation (from March 15, 2026 to April 18, 2026) of the High Court Division of the Supreme Court of Bangladesh.
공시 • Jan 29Beximco Pharmaceuticals Limited Announces Board ChangesBeximco Pharmaceuticals Limited announced that Ms. Quamrun Naher Ahmed, a Non-Executive Director since 30 November 2020, has been replaced by Mr. Mohammed Ebtadul Islam, both with immediate effect. Mr. Islam, like Ms. Ahmed previously, has been nominated to this position by IFIC Bank PLC, a shareholder in the Company, and he will serve as a Non-Executive Director. Mr. Islam has extensive expertise in finance and management at a senior level, having worked at Bangladesh Bank, the central bank of Bangladesh, for 33 years, retiring as an Executive Director in 2014. He currently serves as an independent director of IFIC Bank PLC. He is also a Supernumerary Professor at the Bangladesh Institute of Bank Management (BIBM), the national educational institute on banking and finance in Bangladesh.
공시 • Jan 23Beximco Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 28, 2025Beximco Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 28, 2025
공시 • Dec 30Beximco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended on 30 June 2024, Payable on or Before 28 January 2025Beximco Pharmaceuticals Limited announced that at the AGM held on 29 December 2024, the resolutions passed at the AGM included the approval of 40% cash dividend for the year ended on 30 June 2024. The cash dividend being 40% of the nominal value per ordinary share of BDT 10 (BDT 4.0 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR holders' as on the date of record, i.e. 25 November 2024) on or before 28 January 2025. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.
공시 • Nov 08Beximco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024Beximco Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 13, 2024
공시 • Oct 30Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024, at 10:30 Central Asia Standard Time.
공시 • Oct 23Beximco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024Beximco Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 28, 2024
공시 • Apr 24Beximco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024Beximco Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 29, 2024
공시 • Jan 22Beximco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024Beximco Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 29, 2024
공시 • Jan 12Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing DirectorBeximco Pharmaceuticals Limited announced stepping down of Mr. Nazmul Hassan MP as Managing Director with immediate effect. This follows an invitation from the Prime Minister for Mr. Hassan to join the newly formed Cabinet as a Minister after the recent Bangladesh Parliamentary Election on 7 January 2024.
공시 • Jan 11Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the BoardBeximco Pharmaceuticals Limited announced stepping down of Mr. Nazmul Hassan as Member of the Board with immediate effect. The process to find a replacement will commence immediately and the Company will provide an update at the appropriate time.
공시 • Oct 30Beximco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 05, 2023Beximco Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 05, 2023
공시 • Oct 20+ 2 more updatesBeximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023, at 10:30 Coordinated Universal Time.
공시 • Jan 19Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022Beximco Pharmaceuticals Limited announced that the 35% cash dividend of the nominal value per ordinary share/GDR (Taka 3.50 per ordinary share/GDR) for the year ended 30 June 2022, which was approved in the Annual General Meeting ("AGM") held on 22 December 2022, has been deposited with the custodian bank in Dhaka on 18 January 2023 for onward credit to respective GDR holders' accounts.